

Accepted Manuscript

Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom

Richa Sinha, William Ken Redekop

PII: S2152-2650(17)31702-0

DOI: [10.1016/j.clml.2017.12.005](https://doi.org/10.1016/j.clml.2017.12.005)

Reference: CLML 1045


To appear in: *Clinical Lymphoma, Myeloma and Leukemia*

Received Date: 5 November 2017

Accepted Date: 26 December 2017

Please cite this article as: Sinha R, Redekop WK, Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom, *Clinical Lymphoma, Myeloma and Leukemia* (2018), doi: [10.1016/j.clml.2017.12.005](https://doi.org/10.1016/j.clml.2017.12.005).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Title:

Cost-effectiveness of ibrutinib compared to obinutuzumab plus chlorambucil in untreated chronic lymphocytic leukemia patients with comorbidities in the United Kingdom

Author names and affiliations:

Richa Sinha¹ and William Ken Redekop¹

¹ Erasmus School of Health Policy & Management, Erasmus University Rotterdam, PO Box 1738, 3000DR Rotterdam, The Netherlands

Corresponding author:

Richa Sinha, sinha.richa@hotmail.com

Permanent address:

Melkzwamsingel 16, 3451HN Vleuten, The Netherlands

Conflict of interest:

None

Download English Version:

<https://daneshyari.com/en/article/8615662>

Download Persian Version:

<https://daneshyari.com/article/8615662>

[Daneshyari.com](https://daneshyari.com)